ES2177967T3 - Procedimiento de inhibicion de una respuesta inmune bloqueando las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso. - Google Patents

Procedimiento de inhibicion de una respuesta inmune bloqueando las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso.

Info

Publication number
ES2177967T3
ES2177967T3 ES97916037T ES97916037T ES2177967T3 ES 2177967 T3 ES2177967 T3 ES 2177967T3 ES 97916037 T ES97916037 T ES 97916037T ES 97916037 T ES97916037 T ES 97916037T ES 2177967 T3 ES2177967 T3 ES 2177967T3
Authority
ES
Spain
Prior art keywords
immune response
ctla4
compositions
binding
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916037T
Other languages
English (en)
Other versions
ES2177967T5 (es
Inventor
Christian P Larsen
Alejandro A Aruffo
Diane L Hollenbaugh
Peter S Linsley
Jeffrey A Ledbetter
Thomas C Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Bristol Myers Squibb Co
Original Assignee
Emory University
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21761563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177967(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emory University, Bristol Myers Squibb Co filed Critical Emory University
Publication of ES2177967T3 publication Critical patent/ES2177967T3/es
Application granted granted Critical
Publication of ES2177967T5 publication Critical patent/ES2177967T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN PROCEDIMIENTO PARA INHIBIR UNA RESPUESTA INMUNE, ASI COMO PARA INHIBIR EL RECHAZO DE TEJIDOS TRASPLANTADOS. EL PROCEDIMIENTO COMPRENDE PREVENIR QUE UNA MOLECULA ENDOGENA DE UNA CELULA SELECCIONADA ENTRE EL GRUPO FORMADO POR LOS ANTIGENOS GP39 Y CD40 FIJE SU LIGANDO ENDOGENO, E IMPEDIR QUE UNA MOLECULA ENDOGENA DE UNA CELULA SELECCIONADA DEL GRUPO FORMADO POR LOS ANTIGENOS CTLA4, CD28 Y B7 FIJEN SU LIGANDO ENDOGENO. LA PREVENCION DE TALES MOLECULAS DE LA FIJACION DE SU LIGANDO BLOQUEA DE ESE MODO DOS VIAS INDEPENDIENTES DE SEÑALIZACION E INHIBE LA RESPUESTA INMUNE QUE PROVOCA EL RECHAZO DEL TEJIDO TRASPLANTADO.
ES97916037T 1996-03-20 1997-03-20 Procedimientos para inhibir una respuesta inmune mediante bloqueo de las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso. Expired - Lifetime ES2177967T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1375196P 1996-03-20 1996-03-20
US13751P 1996-03-20

Publications (2)

Publication Number Publication Date
ES2177967T3 true ES2177967T3 (es) 2002-12-16
ES2177967T5 ES2177967T5 (es) 2009-12-17

Family

ID=21761563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916037T Expired - Lifetime ES2177967T5 (es) 1996-03-20 1997-03-20 Procedimientos para inhibir una respuesta inmune mediante bloqueo de las rutas gp39/cd40 y ctla4/cd28/b7 y composiciones para su uso.

Country Status (13)

Country Link
US (4) US5916560A (es)
EP (1) EP0892643B2 (es)
JP (1) JP4751493B2 (es)
AT (1) ATE219376T1 (es)
AU (1) AU710998B2 (es)
CA (1) CA2246352C (es)
DE (1) DE69713499T3 (es)
DK (1) DK0892643T4 (es)
ES (1) ES2177967T5 (es)
IL (1) IL125928A (es)
NO (1) NO326922B1 (es)
PT (1) PT892643E (es)
WO (1) WO1997034633A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
PL193966B1 (pl) * 1997-01-10 2007-04-30 Biogen Idec Ma Zastosowanie przeciwciał przeciwko CD40L lub pochodnych
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
EA002549B1 (ru) * 1997-05-17 2002-06-27 Байоджен, Инк. Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата
WO1998056417A1 (en) * 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
IL133303A0 (en) * 1997-06-20 2001-04-30 Biogen Inc Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
JP4584447B2 (ja) * 1997-11-07 2010-11-24 トリリアム・セラピューティクス・インコーポレイテッド 免疫調節のための方法および組成物
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
CA2319448A1 (en) * 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
EP1637146A3 (en) * 1998-07-30 2008-02-20 The Regents Of The University Of Minnesota Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists
JP2002526455A (ja) * 1998-09-21 2002-08-20 ジェネティックス インスティテュート インク． 治療用たんぱく質に対する免疫応答を下方変調する方法
WO2000039294A1 (en) * 1998-12-24 2000-07-06 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
EP2039368A3 (en) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
ATE360031T1 (de) * 2000-01-03 2007-05-15 Tr Associates L L C Chimäre proteine und anwendungen
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7427665B2 (en) * 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002083162A1 (en) * 2001-04-13 2002-10-24 University Of Chicago Use of a cd8+ t cell inhibitory agent in the presence of a cd4+ t cell inhibitory agent for inhibition of transplant rejection
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
WO2005018668A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8986684B2 (en) * 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
US20190335726A1 (en) * 2016-06-14 2019-11-07 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
CA2086325C (en) * 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994008619A1 (en) * 1992-10-08 1994-04-28 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0784482A2 (en) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
ATE288487T1 (de) * 1995-06-05 2005-02-15 Univ Washington Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PL204899B1 (pl) * 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4

Also Published As

Publication number Publication date
NO984369L (no) 1998-11-18
CA2246352A1 (en) 1997-09-25
DK0892643T4 (da) 2009-12-14
US5916560A (en) 1999-06-29
DE69713499T2 (de) 2003-01-30
NO326922B1 (no) 2009-03-16
US20090186037A1 (en) 2009-07-23
JP4751493B2 (ja) 2011-08-17
DE69713499T3 (de) 2010-05-06
EP0892643A1 (en) 1999-01-27
JP2001518066A (ja) 2001-10-09
CA2246352C (en) 2011-11-08
DE69713499D1 (de) 2002-07-25
US20050202011A1 (en) 2005-09-15
PT892643E (pt) 2002-09-30
ATE219376T1 (de) 2002-07-15
IL125928A0 (en) 1999-04-11
EP0892643B2 (en) 2009-09-02
NO984369D0 (no) 1998-09-18
DK0892643T3 (da) 2002-10-14
IL125928A (en) 2002-11-10
WO1997034633A1 (en) 1997-09-25
US20020031510A1 (en) 2002-03-14
ES2177967T5 (es) 2009-12-17
AU2331097A (en) 1997-10-10
EP0892643B1 (en) 2002-06-19
AU710998B2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
PT892643E (pt) Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
ATE393991T1 (de) Optische übertragungssysteme mit optischen schutzsystemen, vorrichtungen und verfahren
MX2023014274A (es) Compuestos indol sustituidos y metodos de uso de los mismos.
ES2137152T3 (es) Composicion a base de polimero de estireno.
DK263481A (da) Fremgangsmaade til fremstilling af substituerede tricycliske forbindelser
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
ES2177789T3 (es) Peptidos antagonistas de lhrh.
MX9701497A (es) Polimeros de ioneno que contienen aniones biologicamente activos.
ES2176329T3 (es) Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos.
BR0207549A (pt) Compostos tricìclicos moduladores de receptor de androgênio e métodos
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
DK1056454T3 (da) Anvendelse af makrolidforbindelser til behandling af glaukom
ATE453406T1 (de) Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
ES2126280T3 (es) Composiciones y metodos para controlar la reactividad entre reactivos diagnosticos y microorganismos.
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
BR0309850A (pt) Ensaios de qualidade para células apresentando antìgeno
ES2085574T3 (es) P-fenilendiaminas sustituidas por un grupo amonio cuaternario y un grupo aceptor de electrones.
ES2020136A6 (es) Procedimiento para preparar una composicion solida plaguicida emulsionable.
MX9306937A (es) Compuestos aromaticos yodados.
DOP2006000231A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ES2055472T3 (es) Estabilizacion de poliisocianatos organicos.
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
CR20240489A (es) Agentes aglutinantes 5t4 y usos de los mismos